BioCentury | Nov 3, 2014
Company News

Pain Therapeutics Inc., King deal

...28, 2013). Pfizer gained Remoxy and other abuse-resistant opioid painkillers through its 2011 acquisition of King Pharmaceuticals Inc....
...see BioCentury, July 4, 2011 & Nov. 14, 2005). Pain Therapeutics Inc. (NASDAQ:PTIE), Austin, Texas King Pharmaceuticals Inc....
BioCentury | Oct 20, 2014
Clinical News

Embeda morphine/naltrexone regulatory update

...naltrexone in the U.S. early next year. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Oct 18, 2014
Company News

FDA approves abuse-deterrent labeling for Embeda

...available in the U.S. early next year. It gained the product through its acquisition of King Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Morphine/naltrexone regulatory update

...needed for an extended period of time. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Embeda morphine/naltrexone regulatory update

...needed for an extended period of time. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jun 30, 2014
Clinical News

Oxycodone-naltrexone: Additional Phase III data

...chronic low back pain in late 2014. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jun 30, 2014
Clinical News

Oxycodone-naltrexone: Clinical trial data

...chronic low back pain in late 2014. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Apr 21, 2014
Company News

Acura, Pfizer deal

...advice on promotional materials. Pfizer gained rights to the products through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jan 27, 2014
Clinical News

Oxycodone-naltrexone: Phase III data

...for which alternative treatment options are inadequate. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jan 24, 2014
Clinical News

Pfizer's ALO-02 meets in Phase III pain trial

...an extended-release oxycodone hydrochloride surrounding sequestered naltrexone hydrochloride -- through its 2011 acquisition of King Pharmaceuticals Inc. BC...
Items per page:
1 - 10 of 285
BioCentury | Nov 3, 2014
Company News

Pain Therapeutics Inc., King deal

...28, 2013). Pfizer gained Remoxy and other abuse-resistant opioid painkillers through its 2011 acquisition of King Pharmaceuticals Inc....
...see BioCentury, July 4, 2011 & Nov. 14, 2005). Pain Therapeutics Inc. (NASDAQ:PTIE), Austin, Texas King Pharmaceuticals Inc....
BioCentury | Oct 20, 2014
Clinical News

Embeda morphine/naltrexone regulatory update

...naltrexone in the U.S. early next year. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Oct 18, 2014
Company News

FDA approves abuse-deterrent labeling for Embeda

...available in the U.S. early next year. It gained the product through its acquisition of King Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Morphine/naltrexone regulatory update

...needed for an extended period of time. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Embeda morphine/naltrexone regulatory update

...needed for an extended period of time. Pfizer gained Embeda through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jun 30, 2014
Clinical News

Oxycodone-naltrexone: Additional Phase III data

...chronic low back pain in late 2014. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jun 30, 2014
Clinical News

Oxycodone-naltrexone: Clinical trial data

...chronic low back pain in late 2014. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Apr 21, 2014
Company News

Acura, Pfizer deal

...advice on promotional materials. Pfizer gained rights to the products through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jan 27, 2014
Clinical News

Oxycodone-naltrexone: Phase III data

...for which alternative treatment options are inadequate. Pfizer gained ALO-02 through its 2011 acquisition of King Pharmaceuticals Inc....
BioCentury | Jan 24, 2014
Clinical News

Pfizer's ALO-02 meets in Phase III pain trial

...an extended-release oxycodone hydrochloride surrounding sequestered naltrexone hydrochloride -- through its 2011 acquisition of King Pharmaceuticals Inc. BC...
Items per page:
1 - 10 of 285